2.7184
price down icon2.52%   -0.0716
 
loading
Schlusskurs vom Vortag:
$2.79
Offen:
$2.8
24-Stunden-Volumen:
252.90K
Relative Volume:
0.97
Marktkapitalisierung:
$179.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-71.17M
KGV:
-1.7538
EPS:
-1.55
Netto-Cashflow:
$-70.97M
1W Leistung:
-20.71%
1M Leistung:
-48.49%
6M Leistung:
-42.13%
1J Leistung:
-28.99%
1-Tages-Spanne:
Value
$2.63
$2.8037
1-Wochen-Bereich:
Value
$2.63
$3.48
52-Wochen-Spanne:
Value
$2.63
$7.795

Inozyme Pharma Inc Stock (INZY) Company Profile

Name
Firmenname
Inozyme Pharma Inc
Name
Telefon
857-330-4340
Name
Adresse
321 SUMMER STREET, BOSTON
Name
Mitarbeiter
59
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
INZY's Discussions on Twitter

Vergleichen Sie INZY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
INZY 2.715 179.23M 0 -71.17M -70.97M -1.55
VRTX 449.81 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.23 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 588.46 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 247.98 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.53 24.89B 3.30B -501.07M 1.03B 11.54

Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-12 Eingeleitet Stifel Buy
2024-08-13 Fortgesetzt Jefferies Buy
2024-05-30 Eingeleitet Wells Fargo Overweight
2023-03-23 Hochstufung Jefferies Hold → Buy
2022-05-26 Eingeleitet Jefferies Hold
2022-02-07 Eingeleitet H.C. Wainwright Buy
2021-11-29 Eingeleitet Needham Buy
2020-08-18 Eingeleitet BofA Securities Buy
2020-08-18 Eingeleitet Cowen Outperform
2020-08-18 Eingeleitet Piper Sandler Overweight
2020-08-18 Eingeleitet Wedbush Outperform
Alle ansehen

Inozyme Pharma Inc Aktie (INZY) Neueste Nachrichten

pulisher
02:11 AM

Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

02:11 AM
pulisher
Nov 20, 2024

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - MSN

Nov 20, 2024
pulisher
Nov 17, 2024

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St

Nov 17, 2024
pulisher
Nov 15, 2024

Inozyme Pharma stock hits 52-week low at $3.23 amid market shifts - Investing.com

Nov 15, 2024
pulisher
Nov 14, 2024

Eventide Asset Management's Strategic Acquisition of Inozyme Pha - GuruFocus.com

Nov 14, 2024
pulisher
Nov 11, 2024

Inozyme Pharma to Present at Upcoming Investor Conferences - GlobeNewswire

Nov 11, 2024
pulisher
Nov 11, 2024

Inozyme Pharma CEO to Present at Stifel and Jefferies Healthcare Conferences | INZY Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 10, 2024

Inozyme Pharma’s (INZY) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Inozyme Pharma (NASDAQ:INZY) Given “Outperform” Rating at Wedbush - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimates for Inozyme Pharma Increased by Analyst - Defense World

Nov 08, 2024
pulisher
Nov 08, 2024

Inozyme Pharma FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

FY2024 EPS Estimates for Inozyme Pharma Raised by Analyst - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Piper Sandler raises Inozyme Pharma target to $43 from $40 - Investing.com India

Nov 06, 2024
pulisher
Nov 06, 2024

Inozyme Pharma's (INZY) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Inozyme Pharma's (INZY) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Inozyme Pharma’s Q3 2024 Financial and Clinical Progress - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Piper Sandler raises Inozyme Pharma target to $43 from $40 By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

Inozyme Pharma Reports Wider Q3 Loss, Advances Key Clinical Trials Despite $24.6M Loss | INZY Stock News - StockTitan

Nov 05, 2024
pulisher
Oct 27, 2024

Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $16.14 - MarketBeat

Oct 27, 2024
pulisher
Oct 27, 2024

Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World

Oct 27, 2024
pulisher
Oct 25, 2024

Needham & Company LLC Reiterates Buy Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Inozyme reports positive trial results for kidney disease therapy - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Inozyme reports positive trial results for kidney disease therapy By Investing.com - Investing.com Canada

Oct 24, 2024
pulisher
Oct 24, 2024

Inozyme Pharma Bullish on Treatment for End-Stage Kidney Disease - MarketWatch

Oct 24, 2024
pulisher
Oct 24, 2024

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewswire

Oct 24, 2024
pulisher
Oct 21, 2024

The Manufacturers Life Insurance Company Grows Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Oct 21, 2024
pulisher
Oct 18, 2024

(INZY) Proactive Strategies - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 18, 2024

Inozyme Pharma presents kidney disease study at ASN Kidney Week By Investing.com - Investing.com Nigeria

Oct 18, 2024
pulisher
Oct 17, 2024

Inozyme Pharma presents kidney disease study at ASN Kidney Week - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Inozyme Pharma Announces Presentation of Interim Data from - GlobeNewswire

Oct 17, 2024
pulisher
Oct 16, 2024

Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 6.9% - MarketBeat

Oct 16, 2024
pulisher
Oct 12, 2024

Dimensional Fund Advisors LP Purchases 205,417 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Bought by Dimensional Fund Advisors LP - MarketBeat

Oct 12, 2024
pulisher
Oct 10, 2024

Millennium Management LLC Acquires 1,084,341 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat

Oct 10, 2024
pulisher
Oct 08, 2024

Cubist Systematic Strategies LLC Invests $84,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Oct 08, 2024
pulisher
Oct 08, 2024

Inozyme Pharma appoints new board member - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

Inozyme Pharma appoints new board member By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme Pharma Welcomes New Director Erik Harris - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme appoints Erik Harris to board of directors - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme Pharma Appoints Erik Harris to its Board of Directors - citybiz

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its - The Bakersfield Californian

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors - GlobeNewswire

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of - EIN News

Oct 07, 2024
pulisher
Oct 07, 2024

How the (INZY) price action is used to our Advantage - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 05, 2024

Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by American Century Companies Inc. - Defense World

Oct 05, 2024
pulisher
Oct 02, 2024

Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Oct 02, 2024
pulisher
Sep 30, 2024

Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat

Sep 30, 2024

Finanzdaten der Inozyme Pharma Inc-Aktie (INZY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):